drugset / Trial / NCT04364009
Anakinra for COVID-19 Respiratory Symptoms
Phase 3
Terminated
71 enrolled
University Hospital, Tours
INSERM CIC-P 1415, University Hospital Center of Tours · collabSwedish Orphan Biovitrum · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The main objective of the ANACONDA-COVID-19 trial is to assess the efficacy of Anakinra + optimized Standard of Care (oSOC) as compared to oSOC alone on the condition of patients with COVID-19 infection and worsening respiratory symptoms. Success defined as patient alive and free of invasive mechanical ventilation (IMV) and free of Extracorporeal Membrane Oxygenation (ECMO) at Day 14.
Timeline
- Start
- 2020-04-27
- Primary completion
- 2020-10-20
- Completion
- 2020-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anakinra | Protein / enzyme biologic | 200 mg | Intravenous |